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Here we begin by reviewing the spectrum of EZH2 and H3K27 perturbations found in cancer and then synthesize a perspective that unites the function of EZH2 as a master regulator of transcription.
We then review the development, translation and early clinical findings from therapeutic targeting of EZH2.
Mutations resulting in gain of function of EZH2 in cancer EZH2 is the enzymatically active core subunit of the PRC2 complex, which also includes EED, SUZ12, RbAp46 and RbAp48. PRC2 methylates H3K27 (refs. 14,15) , which facilitates chromatin compaction and gene silencing (Fig. 1) . Several lines of evidence have implicated EZH2 in the development and progression of a variety of cancers. An early indication of a role for EZH2 in prostate cancer came from the observation that EZH2 overexpression is associated with worse progression of prostate cancer 16 . Similar findings have emerged in other human cancers including breast cancer, bladder cancer, endometrial cancer and melanoma, as high levels of EZH2 were shown to correlate with aggressiveness and advanced disease in each of these cancer types [16] [17] [18] [19] (Table 1) . EZH2 has been shown to be essential for proliferation of cancer cell lines, and, independently, ectopic EZH2 expression has been found to confer a proliferative advantage upon noncancerous cells 17 . Forced expression of EZH2 leads to the development of myeloproliferative disorder in mice 20 . In an immortalized human epithelial cell line, expression of EZH2 causes neoplastic transformation of breast epithelial cells, a phenotype that is dependent upon the protein's methyltransferase domain 21 .
Additional findings to support an oncogenic role for EZH2 have more recently emerged. Studies have shown that recurrent heterozygous point mutations affecting tyrosine 641 (Y641) within the C-terminal catalytic SET domain of EZH2 occur in 22% of germinal center B cell (GCB) diffuse large-cell B cell lymphomas (DLBCL) and in 7%-12% of follicular lymphomas 22, 23 (Table 1) . The Y641 mutation was initially thought to be a loss-of-function mutation. However, in vitro biochemical enzymatic assays subsequently showed that the mutation confers gain of function of enzyme activity resulting in increased levels of trimethylated H3K27 (H3K27me3) 24 . Mutations of Y641 (Y641F, Y641N, Y641S, Y641C and Y641H) result in reduced methylation of unmethylated H3K27 but enhanced methylation of the dimethylated version of H3K27 (H3K27me2). The mutant protein thus cooperates with wild-type EZH2 to shift the steady state of H3K27 modification so as to favor trimethylation and thus repress expression of Polycomb targets 25 . EZH2 point mutations at the alanine 677 and 687 (A677 and A687) residues have also been identified in non-Hodgkin's lymphomas (NHL), where they similarly result in high levels of H3K27me3 (refs. 26,27) .
Additional support for a gain-of-function role of mutant EZH2 in cancer comes from the identification of cancer-associated loss-offunction mutations affecting other chromatin regulators that normally antagonize EZH2 activity. UTX (ubiquitously transcribed tetratricopeptide repeat gene on X chromosome) is a histone demethylase that functions in part by antagonizing EZH2 activity through the removal of methyl groups from H3K27me2 and H3K27me3. Inactivating mutations affecting UTX occur in several types of human cancer, including multiple myeloma, medulloblastoma, and esophageal, bladder, pancreatic and renal cancers 8, [28] [29] [30] . These mutations include homozygous (in females) or hemizygous (in males) large deletions, nonsense mutations, small frameshifting insertions or deletions, and consensus splice site mutations that create premature termination codons 31 . Almost all mutations are predicted to result in the loss of the JmjC domain of UTX, which is essential for its demethylase activity, and have been shown to cause increased levels of H3K27 trimethylation 31, 32 . Consequently, the loss-of-function mutations in UTX may have analogous effects to those caused by gain-of-function mutations in EZH2.
Genetic studies in many different organisms have also revealed an evolutionarily conserved antagonistic relationship between Polycomb proteins and SWI-SNF complexes, which hydrolyze ATP to remodel chromatin [33] [34] [35] [36] . SWI-SNF complexes comprise 12-15 subunits, which have collectively been found to be mutated in 20% of all human cancers 37, 38 . Unopposed EZH2 activity also promotes cancers driven by loss of the SWI-SNF core subunit SNF5 (also known as SMARCB1) as originally shown in malignant rhabdoid tumor, a highly aggressive type of pediatric cancer 39, 40 . Recent studies have extended this antagonistic relationship to cancers linked to the inactivation of other SWI-SNF subunits, as EZH2 inhibition is synthetic lethal in ovarian cancer xenografts mutant for the SWI-SNF subunit ARID1A and sensitizes lung cancer xenografts mutant for the SWI-SNF ATPase core subunit BRG1 (also known as SMARCA4) to chemotherapy in mice 41, 42 . Most recently, a broad role for EZH2 in progression of cancers that have mutations affecting the SWI-SNF tumor suppressor subunits ARID1A, PBRM1 and SMARCA4 has been demonstrated in both cell lines and in vivo models 43 . Notably, a noncatalytic role for EZH2 was identified in this context, indicating that dependency upon EZH2 for cancer progression can be derived from both catalytic and noncatalytic functions of EZH2. Figure 1 The PRC2 complex and its function in transcriptional regulation. (a) The mammalian PRC2 complex consists of four core subunits: the catalytic subunit enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), suppressor of zeste 12 (SUZ12), and retinoblastoma (Rb)-associated proteins 46/48 (RbAp46/48); additional proteins, including AEBP2, PHF1 and JARID2, have also at times been found to associate with the PRC2 complex to modulate its activity in different contexts. MTF2 and PHF19 are isotypes of PHF1. (b) EZH2 regulates transcriptional activity: as part of PRC2, EZH2 methylates histone 3 at lysine 27 (H3K27), which contributes to transcriptional silencing, EZH2 also has a PRC2-independent role in transcriptional activation and is capable of methylating a number of non-histone protein substrates. OFF and ON refer to transcriptional silencing and activation, respectively. 
Mechanism of EZH2 oncogenic activity
The extensive evidence linking EZH2 activity to cancer has prompted interest in the underlying mechanism. EZH2 and the PRC2 complex are known to be recruited to specific loci during development to silence genes associated with alternative fates [44] [45] [46] . Analogous to its role in normal stem cells, where EZH2 suppresses differentiation by repressing lineage-specifying factors [45] [46] [47] , it is expressed at higher levels in cancer stem cell (CSC) populations isolated from human breast cancer xenografts and primary breast tumor cells, as compared to noncancer cell lines, and is essential for the maintenance of these stem cell populations 48 . In at least some CSC models, EZH2 suppresses expression of genes associated with lineage specification, leading to the hypothesis that EZH2 facilitates transformation by blocking differentiation 47, 49 . However, it is important to note that EZH2 is also essential in facilitating some differentiation programs of several tissue types 50, 51 . Ultimately, the central function of EZH2 and PRC2 during development may not be to promote either stemness or differentiation per se, but rather to suppress transcriptional programs that underlie alternate fates. Thus, the consequences for fate control of perturbing EZH2 are likely to be highly cell type specific. Given its role as a transcriptional regulator, substantial efforts have been dedicated to the identification of downstream targets or pathways that contribute to transformation driven by EZH2. EZH2 has been shown to be downstream of the cell cycle-regulatory retinoblastoma-E2F pathway and is in turn required for the expression of proliferative genes and for E2F-driven proliferation 17 . The Ink4a/Arf tumor suppressor locus (also known as CDKN2A) is thought to be another key target that can be silenced by Polycomb activity, and EZH2-mediated silencing of E-cadherin (also known as CDH1) and FOXC1 and DNA-damage repair pathways has also been shown to contribute to oncogenesis 48, [52] [53] [54] . An unresolved question with potential therapeutic relevance is whether any EZH2 targets are universally essential for EZH2-mediated transformation independent of cell lineage or whether EZH2-induced oncogenic transcriptional changes are context specific depending upon cancer type and cell of origin.
Several studies have also identified a PRC2-independent function of EZH2 in transcriptional activation rather than repression [55] [56] [57] [58] ( Fig. 1) . In a model of castration-resistant prostate cancer, the oncogenic function of EZH2 was shown to be independent of its role as a Polycomb transcriptional repressor and instead due to a PRC2-independent coactivator role of EZH2 for transcription factors, including the androgen receptor (AR) 59 . A gene activation role of EZH2 was also demonstrated in breast cancer cells in which EZH2 first activates NF-κB targets or NOTCH1 (refs. 57,58) . EZH2 has also been implicated in transcriptional activation of gene expression in breast cancer, where it has been shown to induce the expression of genes that are regulated by the estrogen receptor (ER) and Wnt signaling transcription factors by physically bridging between the ER and components of Wnt signaling (β-catenin) 55 .
In addition to its known roles in histone modification and transcriptional regulation, EZH2 can methylate non-histone substrates. EZH2 binds and methylates STAT3, which promotes tumorigenicity of CSCs in glioblastoma; and in a prostate cancer model, EZH2 has been shown to methylate the AR, modulating AR recruitment to the sites bound by both AR and EZH2 (refs. 59,60) . EZH2 has also been implicated in the methylation of non-histone substrates; this mechanism may facilitate recognition by the ubiquitination machinery, driving degradation of the methylated proteins 61, 62 . Collectively, these results suggest that in addition to its known role as an H3K27 histone methyltransferase and transcriptional suppressor, EZH2 may also have PRC2-independent roles as a transcriptional coactivator and directly modulate the activity of transcription factors and other proteins. However, the contribution of these noncanonical functions to the overall cellular role of EZH2, and their link to any role of EZH2 in oncogenic transformation, remain unclear.
EZH2 as a therapeutic target
Given the evidence for EZH2 enzymatic gain of function being a cancer driver, the development of EZH2-specific inhibitors has been an active area of investigation, and multiple biotech and pharmaceutical companies have been pursuing such compounds. Promising preclinical results have been obtained and human phase 1 trials are now underway, with early results suggesting potential clinical activity ( Table 2) .
Enzymatic inhibition of EZH2. The first EZH2 inhibitor that was widely used for experimental work was 3-deazaneplanocin A (DZNep). This is a cyclopentanyl analog of 3-deazaadenosine that potently interferes with S-adenosyl-l-homocysteine hydrolase (SAH), a component of the methionine cycle, which causes cellular SAH levels to increase, repressing the activity of S-adenosyl-l-methionine-dependent histone lysine methyltransferase activity 63 . Therefore, the effect of DZNep in inhibiting histone methylation is not specific to EZH2. Treatment with DZnep induces significant antitumor activity in various cancer types, corresponding with inhibition of PRC2 and removal of H3K27me3 marks 64 . In spite of potentially promising results in vitro and in vivo, DZNep has a very short plasma half-life, confers nonspecific inhibition of histone methylation and is toxic in animal models 65 .
In order to improve antitumor activity and reduce toxicity, significant efforts have been directed toward developing compounds that are potent and selective inhibitors of EZH2. High-throughput Many of these compounds require frequent injection, and hence UNC1999 was synthesized as the first orally bioavailable inhibitor that was highly selective for wild-type EZH2 and the EZH2 Y641 mutant. UNC1999 is also relatively active against EZH1, with only tenfold less potency than for EZH2, thereby offering the potential to target EZH2 and EZH1 together (ref. 70) . EPZ-6438, developed subsequently, has greater potency than EPZ005687 and better pharmacokinetic properties than EPZ005687, including good oral bioavailability 71 . Treatment of mice carrying SMARCB1-mutant malignant rhabdoid tumors with EPZ-6438 resulted in decreased levels of H3K27me3 and dose-dependent tumor regression 72 . In June 2013, a phase 1/2 clinical trial of EPZ-6438 in patients with advanced solid tumors or with B cell lymphomas was launched (NCT01897571). Preliminary reports from the study have been presented at scientific meetings (http://www.epizyme.com/ wp-content/uploads/2014/11/Ribrag-ENA-FINAL.pdf and http://www. epizyme.com/wp-content/uploads/2015/07/ICML-Slides-Presented-062015-v2.pdf). The data show potentially encouraging activity of the drug: partial or complete responses were observed in 9 of 15 patients with NHL, including a partial response in the one patient who had an EZH2 mutation (EZH2 Y646H) and one complete response and partial responses in malignant rhabdoid tumor patients. Two other clinical trials (NCT02395601 and NCT02082977) are actively enrolling patients, and further investigation in EZH2-mutant B cell NHL and SMARCB1-deficient tumors are currently being pursued.
Inhibitors that disrupt PRC2 stability. The discovery of nonenzymatic functions for EZH2, and their implication in SWI-SNF-mutant cancers, raise the possibility that the enzymatic inhibitors currently in clinical trials may not fully suppress the transformation-promoting activity of EZH2. EZH2 can also be inhibited by disrupting its interaction with other PRC2 subunits through the use of a peptide known as stabilized alpha-helix of EZH2 (SAH-EZH2) that is derived from the domain of EZH2 that interacts with EED 73 . SAH-EZH2 disrupts the EZH2-EED complex, reduces EZH2 protein levels, and selectively inhibits H3K27 trimethylation in a dose-dependent manner. This peptide is efficacious against EZH2-dependent MLL-AF9 leukemia and EZH2-mutant lymphoma cells but has no effect on nontransformed and EZH2-wild-type controls. Notably, although the antiproliferative effect of the SAH-EZH2 correlated with the reduction in H3K27me3 levels, the effect seemed to correlate even more strongly with reduction of EZH2 protein levels, consistent with the findings of dependence upon nonenzymatic roles of EZH2 in SWI-SNF-mutant cancers 43 .
Therapy resistance and combination therapies Therapy resistance typically enables cancer cells to escape the effects of any single agent, and mechanisms of resistance to EZH2 inhibitors are beginning to emerge. In a cell line model, two novel secondary mutations of EZH2 (Y111L and Y661D) were identified in resistant cells following prolonged exposure to EZH2 inhibitors and were found to cooperate to confer resistance 74 . Separately, it had earlier been reported that loss of PRC2 subunits can amplify Ras-driven transcription in peripheral nervous system tumors, high-grade gliomas and melanomas. Furthermore, co-occurrence of a Ras-pathway mutation with mutations in SWI-SNF correlated with resistance to EZH2 inhibition 75, 76 (Fig. 2) . Consequently, there is interest in identifying therapies that have the potential to cooperate with EZH2 inhibitors. In preclinical models of EZH2-mutant NHL, combining EPZ-6438 with conventional NHL-directed chemotherapy prevented tumor growth in a synergistic manner 77 . The combination of EPZ-6438 and a glucocorticoid receptor agonist (GRag) also enhanced inhibition of proliferation both in cells harboring EZH2 mutations and in germinal-center NHL. In prostate cancer models, combination of the chemotherapeutic agent etoposide with GSK126 significantly increased death of mouse and human prostate cancer cell lines 78 . Finally, in the preclinical study of non-small cell lung cancers, EZH2 inhibition was found to have differing effects in subsets of these cancers as defined by their differing mutations. In tumors that carried Figure 2 EZH2 as a therapeutic target in cancer. (a) The roles of EZH2-mediated transcriptional silencing are context specific. Hyperactive EZH2 can lead to cancer by altering expression of lineage specification genes, the pRB tumor suppressor or DNA-damage repair genes. (b) Cancers with either SWI-SNF mutations or gain-of-function EZH2 mutations can be inhibited by EZH2 inhibition. Early preclinical evidence suggests a potential benefit of combination therapy with an EZH2 inhibitor in these instances. Furthermore, at least in the case of cancers driven by SWI-SNF mutation, mutations in genes of the Ras pathway can confer resistance to EZH2 inhibition. (Topo II) inhibitors. In contrast, in tumors that lacked these mutations, EZH2 inhibition conversely promoted resistance to Topo II inhibitors 42 . Collectively, although the development of EZH2 inhibition as a therapeutic is only in its early stages, evidence of resistance mechanisms is beginning to emerge, as are potential approaches for combination therapy-both areas of ongoing study.
Loss-of-function EZH2 mutations in cancer
Although mutations that result in the overexpression and gain of function of EZH2 seem to have an oncogenic effect, there is also evidence suggesting that EZH2 acts as a tumor suppressor in some cancer types [79] [80] [81] (Table 3) . Recurrent inactivating deletion, frameshift, nonsense and missense mutations in EZH2 occur in a subset of myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and MDS-MPN overlap disorders 80, 81 . Whereas the truncating mutations are dispersed throughout the gene, the missense mutations preferentially occur at highly conserved residues in the domain required for interaction with SUZ12 of PRC2 and the CXC-SET domain required for EZH2 catalytic activity. These mutations can be found in both monoallelic and biallelic states, and individuals whose myeloid disorders carry homozygous mutations have been shown to have reduced survival compared to those with heterozygous mutations 80 . Mice lacking Ezh2 have been found to have enhanced initiation and propagation of Runx1-mutant MDS, consistent with a tumor-suppressive role of EZH2 in MDS 79 .
Loss-of-function mutations and deletions of EZH2 also occur in human T cell acute lymphoblastic leukemia (T-ALL) 82, 83 (Table 3) . Notably, EZH2 is not the only PRC2 subunit affected in this cancer, as missense mutations have been identified in both EZH2 (11 of 68 cases) and SUZ12 (3 of 68 cases) 82 . The frequency of PRC2 mutations is even higher in a pediatric subtype of T-ALL, early T cell precursor (ETP) ALL: deletions and point mutations of EED, EZH2 and SUZ12 are found in 42% of ETP ALL and are also found in 12% of non-ETP pediatric T-ALL 84 . Mutation of genes encoding PRC2 subunits other than EZH2 also occurs in other cancers [85] [86] [87] (Table 3) . In endometrial stromal tumors, fusion of SUZ12 (also known as JJAZ1) with JAZF1 has been identified 86, 87 . Loss-of-function somatic alterations of EED or SUZ12 occur in 70%-90% of malignant peripheral nerve sheath tumors (MPNSTs), where they correspond with complete loss of H3K27me3 and activation of multiple developmentally suppressed pathways 85, 88 . EED mutations that affect EED protein stability, its interaction with EZH2 or its binding to H3K27me3 also occur in a subset of patients with MDS and related diseases, and haploinsufficiency of EED leads to a myeloproliferative disorder in mice [89] [90] [91] .
The canonical substrate of PRC2, lysine residue 27 of histone H3 and its variants, has itself been found to be subject to specific recurrent missense mutations in highly restricted cancer types, including 31% of pediatric glioblastoma multiforme (GBM), 78% of diffuse intrinsic pontine gliomas (DIPG) and 50% of pediatric high-grade gliomas (pHGG) [92] [93] [94] . In vitro, the H3K27M mutation has been shown to block PRC2 activity as it has an increased affinity for the protein, causing it to act as a sink for EZH2 binding and thus inhibit methylation at other H3 sites 94 . Expression of H3.3 K27M also increases H3K27 acetylation (H3K27ac), a modification mutually exclusive with H3K27me3 that correlates with transcriptional activation rather than repression 95 . Therefore, histone H3 mutations may contribute to tumorigenesis through aberrant activation of key regulatory loci by reducing H3K27 trimethylation and facilitating acetylation. Correspondingly, the high frequency of H3K27 mutations in these pediatric brain cancers combined with their rarity in other cancers suggests a highly contextdependent cancer-promoting role, perhaps reflecting perturbation of a role for EZH2 and PRC2 in the regulation of neural stem cell fate. However, mutations of PRC2 subunit genes have not been detected in pediatric GBM or DIPG, so it remains to be determined whether the H3K27M mutations are similar in mechanism of action to EZH2/ PRC2 loss-of-function mutations or whether these mutations exert effects via additional non-Polycomb mechanisms. Collectively, the discoveries that EZH2/PRC2 loss of function can drive oncogenesis in certain contexts suggest that some caution is warranted in the clinical application of EZH2 inhibitors.
Conclusions, questions and future directions
The parallel development and testing of independent EZH2 inhibitors, three of which have now moved to clinical trials, should soon yield a trove of data on the toxicity as well as the potential efficacy of this approach to enzymatic inhibition in cancers that carry a variety of EZH2 activation mechanisms. As only data from patients with EZH2-wild type tumors have been reported thus far, it will be of great interest to determine the efficacy of these inhibitors in cancers that carry activating EZH2 mutations. Given the emerging non-PRC2-based functions of EZH2, it will also be of interest to understand the extent to which EZH2 mutations promote cancer via PRC2-dependent versus -independent effects. Similarly, it will also be important to understand the extent to which the cancer-promoting effects of EZH2 depend upon its enzymatic activity as compared to its nonenzymatic structural contributions to PRC2 integrity as this carries substantial implications for drug development.
Given its clear gain-of-function contributions to cancer and the capability of directly inhibiting its enzymatic function, EZH2 constitutes a compelling target for anticancer therapy, albeit with potential caveats due to its developmental and tumor-suppressor roles. The story of EZH2, from its discovery as a regulator of body patterning in fruit flies to the recognition of its role as a transcriptional regulator of chromatin structure and as a driver of cancer, should soon have a new chapter once clinical trials reveal whether targeting EZH2 can bring a substantial therapeutic advance. 
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